Risk of hyperlactatemia in patients with obstructive sleep apnea receiving metformin: a cross-sectional study
Abstract
Type 2 diabetes is a common comorbidity in individuals with obstructive sleep apnea (OSA). Metformin, one of the most commonly applied therapy options for type 2 diabetes, is known to increase lactate production. Given that OSA may put patients at risk of hyperlactatemia, it is important to examine lactate levels in patients receiving metformin. This study aimed to identify factors affecting lactate concentrations and the consequent risk of hyperlactatemia in this population. A total of 505 patients were included in the study. All underwent a detailed and systematic clinical evaluation and attended diagnostic nocturnal polysomnography. Serum lactate levels were measured at a single time point. Median lactate concentration across the cohort was 1.0 mmol/L and did not differ by OSA severity (p = 0.82). 18.8% of patients used metformin and exhibited higher lactate concentrations compared to those not receiving the medication (p 0.8 mmol/L) were detected in 64.8% of patients. Patients with increased lactate levels were more often active smokers. Multivariable analysis revealed that hyperlactatemia was associated with metformin use (p < 0.001) and active smoking (p = 0.014). Our findings indicate that metformin use in patients with OSA and type 2 diabetes appears to be safe for lactate metabolism, regardless of OSA severity. However, the risk of hyperlactatemia increases in actively smoking patients treated with metformin, which calls for targeted interventions to encourage…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 505 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.